PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Clinical trials for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) trials appear
Sign up with your email to follow new studies for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to stop dangerous bleeding in adults
Disease control Not yet recruitingThis study is testing a specific sequence of three different medications to treat severe immune thrombocytopenia (ITP), a condition where the immune system attacks blood platelets. Adults with very low platelet counts will first receive two drugs in the hospital for two weeks, th…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE4 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug combo aims for Longer-Lasting relief in Tough-to-Treat blood disorder
Disease control Not yet recruitingThis study is testing whether combining two drugs, orelabrutinib and romiplostim, can help people with chronic immune thrombocytopenia (ITP) achieve better and longer-lasting control of their condition. It is for adults who have already tried at least one other treatment. The mai…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for ITP patients when first treatment fails
Disease control Not yet recruitingThis study aims to find the best next-step treatment for ITP patients whose initial platelet-boosting medication didn't work. Researchers will compare switching to a double dose of the original drug (rhTPO) versus switching to a different medication (eltrombopag). The study will …
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New combo therapy aims to control stubborn blood disorder
Disease control Not yet recruitingThis study is testing whether adding a new drug called ianalumab to standard platelet-boosting medications is safe and tolerable for adults with primary immune thrombocytopenia (ITP). Researchers want to see if this combination helps improve platelet counts and allows patients to…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 16, 2026 15:24 UTC